Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04633954
Other study ID # Red Eye 1.0
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 6, 2019
Est. completion date August 31, 2019

Study information

Verified date November 2020
Source Uptown Eye Specialists
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Laser-assisted cataract surgery is a common and precise procedure done to remove cataracts from the eye. This procedure involves putting on a suction cup that applies a mild vacuum seal around the eye to stabilize the eye during the laser procedure. This suction cup often causes some bleeding under the conjunctiva around the eye which takes a few days to disappear. The purpose of this study is to test the use of a well-known eye medication (normally for treating glaucoma) called Brimonidine tartrate 0.15% (or Alphagan-P) in patients having laser-assisted cataract surgery. The use of Brimonidine to reduce bleeding under the conjunctiva is investigational, which means it has not been approved by Health Canada for use outside of research studies like this one. This study will see if Brimonidine will help to reduce bleeding under the conjunctiva in patients having laser-assisted cataract surgery.


Description:

The focus of this study is to assess how the quality of care for patients undergoing Femtosecond laser-assisted cataract surgery (FLACS) can be improved through the application of Brimonidine Tartrate 0.15% prior to the surgery. The surgery consists of the application of a vacuum which can result in subconjunctival hemorrhage, a benign disorder. The importance of this study is due to the considerable alarm and anxiety caused to the patients by the hemorrhage which may cause them to seek our further unnecessary medical help and reduce their ability to return to work or productivity. During the laser component of FLACS, the operated eye is secured with a suction cup or ring with vacuum that causes significant subconjunctival hemorrhage. Brimonidine is a selective alpha-2-adrenergic agonist that is a commonly used as a topical medication to treat glaucoma. Besides its intraocular pressure lowering effect, it also has a vasoconstrictive effect. This latter effect has been exploited to reduce bleeding in LASIK, cataract surgery, strabismus surgery, as well as intravitreal injections. This study will examine the effectiveness of Brimonidine to reduce subconjunctival hemorrhage during Femtosecond laser-assisted cataract surgery. Potential side effects of topical application of Brimonidine eye drop may include blurred or loss of vision, burning, dry, or itching eyes, discharge or excessive tearing, disturbed color perception, double vision, halos around lights, headache, itching of the eye, night blindness, overbright appearance of lights, redness of the eye or inner lining of the eyelid, swelling of the eyelid, tearing of the eye, tunnel vision. The risk of this study to the subject is negligible. To evaluate the degree of subconjunctival hemorrhage occurring in subjects undergoing Femtosecond laser-assisted cataract surgery, following preoperative application of Brimonidine 0.15%. Subconjunctival hemorrhage and its associated bulbar redness will be measured using Bulbar Redness Score using the Oculus M5 following the surgery.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date August 31, 2019
Est. primary completion date August 31, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All patients who are schedules for femtosecond laser assisted cataract surgery who have provided informed consent, in accordance with application regulations and guidelines Exclusion Criteria: - Patients who have been on anticoagulation or antiplatelet therapy - Patients who have undergone any conjunctival surgery in the past - Any complication during cataract extraction

Study Design


Intervention

Drug:
Brimonidine Tartrate 0.15% Oph Soln
One drop of Brimonidine Tartrate 0.15% Oph Soln prior to FLACS

Locations

Country Name City State
Canada Uptown Eye Speicialists Brampton Ontario

Sponsors (1)

Lead Sponsor Collaborator
Uptown Eye Specialists

Country where clinical trial is conducted

Canada, 

References & Publications (5)

Desco MC, Navea A, Ferrer E, Menezo JL. Effect of prophylactic brimonidine on bleeding complications after cataract surgery. Eur J Ophthalmol. 2005 Mar-Apr;15(2):228-32. — View Citation

Hong S, Kim CY, Seong GJ, Han SH. Effect of prophylactic brimonidine instillation on bleeding during strabismus surgery in adults. Am J Ophthalmol. 2007 Sep;144(3):469-70. — View Citation

Kim CS, Nam KY, Kim JY. Effect of prophylactic topical brimonidine (0.15%) administration on the development of subconjunctival hemorrhage after intravitreal injection. Retina. 2011 Feb;31(2):389-92. doi: 10.1097/IAE.0b013e3181eef28e. — View Citation

Norden RA. Effect of prophylactic brimonidine on bleeding complications and flap adherence after laser in situ keratomileusis. J Refract Surg. 2002 Jul-Aug;18(4):468-71. — View Citation

Pasquali TA, Aufderheide A, Brinton JP, Avila MR, Stahl ED, Durrie DS. Dilute brimonidine to improve patient comfort and subconjunctival hemorrhage after LASIK. J Refract Surg. 2013 Jul;29(7):469-75. doi: 10.3928/1081597X-20130617-05. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Bulbar Redness Score Bulbar redness score measured with Oculus 5M Keratograph will detect the amount of redness before and after FLACS. The Oculus Keratograph 5M BR score uses a clinical grading scale of 0.0-4.0 in 0.1 step. A higher score correlates to increased bulbar redness. Pre-operatively
Primary Bulbar Redness Score Bulbar redness score measured with Oculus 5M Keratograph will detect the amount of redness before and after FLACS. The Oculus Keratograph 5M BR score uses a clinical grading scale of 0.0-4.0 in 0.1 step. A higher score correlates to increased bulbar redness. 15 minutes post-operatively
Secondary Analyzed Area Bulbar redness scoring by Oculus 5M Keratograph imaging simultaneously calculates the area analyzed, which will be compared between groups to ensure a similar surface area is measured. Pre-operatively
Secondary Analyzed Area Bulbar redness scoring by Oculus 5M Keratograph imaging simultaneously calculates the area analyzed, which will be compared between groups to ensure a similar surface area is measured. 15 minutes post-operatively
Secondary Attempts of Vacuum The number of attempts it takes to achieve adequate vacuum as part of FLACS will be recorded During the operation
Secondary Duration of surgery The entire duration (start to end) of the surgery will be recorded During the operation
See also
  Status Clinical Trial Phase
Completed NCT02573610 - Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery Phase 3
Completed NCT02910362 - Intra-surgical Evaluation of CATS Tonometer Prism and Abbott Medical Optics Versus Alcon Phacoemulsification Machines N/A
Recruiting NCT01193504 - Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Phase 4
Completed NCT01199510 - Efficacy Evaluation of SYSTANE® ULTRA in Patients Scheduled for Cataract Surgery Phase 4
Completed NCT01455233 - 2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery Phase 4
Completed NCT04146961 - The PanOptix Trifocal IOL: A Study of Patient Satisfaction, Visual Disturbances, and Uncorrected Visual Performance
Completed NCT00585975 - Efficacy and Safety of Bromfenac Ophthalmic Solution Phase 2
Completed NCT00406913 - Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery N/A
Not yet recruiting NCT04131335 - Use of Prophylactic Lubricating Drops After Cataract Surgery N/A
Recruiting NCT05331690 - Cataract Surgery and Inflammation - the Role for Preoperative NSAIDs (Pre-CIN) Phase 4
Withdrawn NCT04563559 - PREFERENTIAL Study Phase 2/Phase 3
Completed NCT04732351 - Evaluation of the Active Sentry System During Cataract Surgery With the Centurion Phacoemulsifier
Completed NCT02128113 - RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD Phase 2
Completed NCT03873454 - The Effects of Music on Perioperative Outcomes in Cataract Surgery N/A
Completed NCT04769856 - Impact of Non-fasting on Anxiety in Cataract Surgery N/A
Withdrawn NCT00604305 - Comperative Trial Between an Accommodative Iol and Monofocal Iol N/A
Completed NCT05925894 - Efficacy Mydrane ® for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma. N/A
Not yet recruiting NCT06136780 - Impact of Free Reading Glasses on Work and Visual Function Following Cataract Surgery in Honduras N/A
Completed NCT03644875 - Study of Etacoat in Patients With Cataract Surgery Via the Anterior Chamber
Recruiting NCT04781231 - Impact of Music Added to the Usual Treatment on the Anxiety of Patients Undergoing Outpatient Cataract Surgery With Topical Anesthesia N/A